µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ Ft<B[bQ
g27)$0&0
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ l]~mB~
g).
IF.
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ 9}$'q$0R]
C Xh>'K
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© -9;XNp
,b9!\OWDF
1. CD4
&Y jUoe
B\\M%!a>
2. T cell receptor(TCR) MuF{STE>->
dhV6r
3. immunoglobulin superfamily (IgSF) W.nr&yiQ
s[Whg!2~
4. selectin GQ6~Si2
j7yUya&
5. anti-idiotypic antibody (¦ÁId) 6kHuKxY,
?/}-
&A"
6. major histocompatibility complex(MHC) Odr<fvV,>
u?SxaGEa
7. immunotolerance e'2w-^7
r<!/!}fE,
8. biological reponse modifier(BRM) d@ef+-
jqQG n"!
9. immune reponse gene (Ir gene) G2w0r,[
n!h952"
10. reshaped antibody (or reconstituted antibody) >6gduD!6I
gg@Ew4L&
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© " nLWvV1
:'Tq5kE
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ /mwsF]Y
bA07zI2
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? $k^&
X
`
o,!W,sx_
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ GpXU&A'r
:nS p
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? !RwMUnp
qRCUkw} fs
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) -SF
5
0.[
:oytJhxU
¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ /;WFRp.
u_.Ig|Va
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? v*^'|QyM7
q
U^`fIa
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? (t"e#b
(:
/gP"X1.
¡¡ yH(%*-S
4YA1~7R
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ ,EH^3ODD
*/j[n$K>~`
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? 5
~Y a Xh^
h%] D[g
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? g3c,x kaO
`86})xz{
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ .x_F4 #Ka
8>'vzc/*>
ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ i .''\
WB\chb%ej#
¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ 7w?N-Q$y
uwu`ms7z 2
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 9%DLdc\z;
-Hg,:re2
1. CD8 #./8inbG
h/7_I uD
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) OGPrjL+
[~k!wipK
3. immunoglobulin fold(Ig fold) 59k-,lyU,
S=3 H.D!f
4. cadherin (Ca-dependent cell adhesion moleculers) $aj:\A0f
kV$VKag*A
5. idiotype-anti-idiotypic antibody immune network theory -{Fy@$!
F*=}}H/
6. HLA class II antigen r_3=+
%
r0AhWv
7. complementarity-determining region (CDR) 7
'{wl,u
ig4mj47wJ
8. perforin(or pore-forming protein ,PFP) yVH>Q-{
jWh}cM=
9. high affinity IL-2 receptor wg|/-q-
q[%SF=~<k{
10. artificial active immunization KHoDD=O
m=%yZ2F;
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© VP:9&?>G
h
F
*c
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠYBQ{/"v%|
dA$qzQ
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 DTCOhUIV
)OV2CP
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ I|)U>bV
z:JJ>mxV
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ 1^ y^b{
VH
x:3G
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) w~WW2w
rY]QTS">o
1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ WS1#i\0
~A-D>.ZH
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? l6< bV#_qe
a<v!5
\dq!
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£
iKEHwm
WXCZ
}l
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ _:VIlg
U
4i(?5p>f
¡¡ t? [8k&Z
YY
8vhnw
%lS jC%Z'd
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ Mt%=z9OLq9
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ 3V@!}@y,F6
utBKl'`
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ bSS=<G9
a_o99lP
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© K1
m'20U
?7R&=B1g
1. immunoglobulin gene rearrangement
D:Fi/JY~
i|QL6e*0
2. the common chain of cytokine receptor (or a cytokine receptor ,nz3S5~
Kp%:\s,lO
subunit shared by some cytokine receptors) NLF
6O9
fkJE lO-F
3. flow cytometry(FCM) 5FwVR3,
D~7L~Q]xI
4. carrier effect < <]uniZ\
|oV_7
%mlu
5. positive selection of T lymphocytes in thymus )9z3T>QW
`nEe-w^9)I
6. mouse TH1(Th1) and TH2(Th2) subsets CC.ri3+.
Gey j`t
7. perforin (pore-forming protein ,PFP) fQ_(2+FM
S F&EVRv
8. ADCC(antibody-dependent cell-mediated cytotoxicity) L5A?9zum/!
W;!)Sj4<T!
9. SH-2(src-homology region 2) ]]8^j='P'
|7%#z~rT
10. Ab2¦Â (internal image) Bf{c4YiF
!\/J|~XZ
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© "*Gp@
.ly K
,p
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? (V9 ;
j/uu&\e
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? eG
j[%
pk
#7|73&u(
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠD%!GY1wdn
sG8G}f
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ )Rr0f 8
>S'IrnH'!
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠsX,S]:X
?OF9{$m3?
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) OS sYmF
xvTz|Y
ÃâÒßѧרҵ£º }B@44HdY
h@%a+ 6b?
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ E8"$vl&c]
'e:(61_
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? 12
HE=
U*:E|'>
´«È¾²¡Ñ§×¨Òµ£º "r[Ob]/
{pk]p~
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ 7mtX/w9
|(3"_
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ {B[ }}wX$
D-4{9[
Ïû»¯×¨Òµ£º 1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹ÔÑо¿µÄ½øÕ¹¡£ P$5K[Y4f
20cEE>
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? MIdV
i
S.g
}No8t o
v W4n>h}]
%uDH_J|^
}56WAP}Z 4
%
Ou'+A
M< /
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ CaR-Yk
vn4z C
ÃâÒßѧÊÔÌâ ]i\;#pj}
c3.;
o
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© J?C:@Q
S? #6{rx
1. Fas(CD95)/FasL ^09-SUl^
8p]9A,Uq&
2. common chain of cytokine receptor
0ZJj5<U
sO{TGk]*
3 . TCR/CD3 complex )3k?{1:
Rqr>B(|
4. negaive selection of thymocytes N-W>tng_x
+QNsI2t;r
5. artificial active immune }=Ul8
<
gloJ;dEB
6. anti-idiotypic FLXn%/
~;#sj&~
7. IgSF OY8P
Q-z `rW
8. Integrin %SuELm
yD#(Iw
9. chemokine `aTw!QBfG
mm;sf
10. B7/CD28 Q[?R{w6
> l]Ble
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© %uCsCl
] E:NmBN<
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£ fv k(eWB
H]7bqr
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ KA{&NFx
8i5S
}
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ Q-rG~O9-
h8X[*Wme
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£ .]s? 01Z
8d_J9Ho
HNCu:$Wr@
*CPp U|
c@Br_-
]YtN6Rq/
,n[<[tkCR
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ D'vaK89\
Cf9{lhE8
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© v?
O
Ud^
TY'c'u,
1. B7/CD28 2x9.>nwhb
*hru);OJr
2. Th1 subset qZ'2M.;
"T{WOGU+
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© 3}!
u8,P
jU~ x^Y
4. antibody affinity maturation &l3(+4Sh
r7oFG!.?
5. AP-1 LWm1j:0
IdN3Ea]
6. single chain variable fragment£¨ScFv£© y: x<`E=
"+T`{$Z=C
7. NK cell receptor tT>LOI_z
gT0yI;g]
8. Zinkernagel-Doherty phenomenon ||>4XDV#
`MCiybl,&P
9. Ig fold &Ap9h#
dK
A5J41yH
10. CD40/CD40L ~ HhB@G!3
.Y{x!Q"
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© x<M::")5!V
6ICW>#fI`
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ F5RL+rU(h
j
:B/ FL
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿
R%RxF=@
D$K'Qk
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ &H%/.4la
<+g77NL
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ / Qd` ?
0S$k;q
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ NGSts\D'}
M%`CzCL
u
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ XJ\R'?j
9>w~B|/
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ }W8A1-UF
nK :YbLdK,
b(GV4%
yy8-t2V
jeWv~JA%L|
K<
*6E@+i
kZz'&xdv'.
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ h'-4nu;*
NplyvjQN;
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© XqmB%g(
~^' ,4<K-}
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© YUEyGhkMV{
x^[,0?y2
1.Co-stimulators (or co-stimulating molecules) aNEah
iibG$?(
2.NK-kB bwXeEA@{
^qR|lA@=\
3.Immunoglobulin superfamily b!@PS$BTxq
7x6M]1F
4.antigen-presenting cell (APC) mp8GHV
pz
/[${X
5.death domain )*]A$\Oc[
:>fT=$i@
6.CCR and CXCR JPqd}:u3
+-@n}xb@
7.Lectin (or mitogen) %i9 e<.Ot
mF;mJq<d
8.Clusters of differentiation, CD) K|Sq_/#+U
cb9-~*1
9.B7 family 4[$:KGh3
TF/NA\0c$
10.Cytotoxic T lymphocyte, CTL)
juOStTq<
K'ZNIRr/C
11.IL-15 and IL-15 receptor (IL-15R) ;0 B1P|7zK
,>-D xS
12.MHC restriction 27D*FItc
Y
bP
@
13.Affinity-chromatography ^w^e~0
S
d&NnpjH}c
14.Cyctosprin A, CsA Q ]CMm2L^f
#%;Uh
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) ~b~Tq
0DicrnH8
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© |!PL"]?
'."_TEIF
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 jKml:)k
g5nJ0=9
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ k77IXT_7u
{nKw<F2
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£ 2#.s{ Bv
0&,D&y%
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© _Xd"'cXw
H4y9\
-
ÃâÒßѧרҵ£º X9Ch
(nWX
UDG1F_&h
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ XjN4EDi+E
QR&e~rks
Ïû»¯ÄÚ¿Æ£º N\PdX$
yu'-'{%
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ FLW VI4*
\n[kzi7
ѪҺ²¡Ñ§×¨Òµ£º $+Ze"E
+aOdaNcI
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿ vIRT$W' O}
tB4mhX|\
}nlS&gew^
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ x4*
bhiu
a$=~1@
(רҵ»ù´¡: ÃâÒßѧ) O >h`
%M
iv8
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) >/A]C$?3
uHKEt[PS$
1. ADCC(antibody dependent cell-mediated cytotoxicity) 9O 'j+?(`@
iN&oSpQ
2. »·æß¾úËØ(cyclosporin) AXlVH%'
Rge>20uTl$
3. KIR(killer cell inhibitory receptor) ;dzL9P9IU
TaRPMKk
4. HLDA(human leucocyte differentiation antigen) b$b;^nly
/wLBmh1"
5. Interleukin 18(IL-18) UQDAql
G!Brt&_'
6. ÕûºÏËØ(integrin) _^&
q,S
!'N@ZZ
7. Fas/FasL %>&ex0j]
Uoe
{,4T
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) y^C5_w(^jZ
)g'J'_Sl
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) 5R
EFz
q@wD@_
10. Th1/Th2 8NfXYR#
_8.TPB]no
11. »ùÒòÒßÃç(DNAÒßÃç) -yf8
E4% -*n
12. chemokines and chemokine receptor a<&K^M&
cTq@"v di
13. ÃâÒßÄÍÊÜ Pdf-2
Tx
6=/sEz S'
14. ¹²´Ì¼¤·Ö×Ó 1L!;lP2
x#`p.sfVo
15. ËÀÍö½á¹¹Óò(death domain) qHub+"2
&za
}THm
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) $rX
CNew(
i9L]h69r
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? c0zcR)=mL
lMFo)4&P
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠS=,czs3N
_]zX W
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î 7y=O!?*
s;I
@En
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ 59zWB,y(P
7"'RE95
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå #//xOL3J
|yk/iO(
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ )xy>:2!#Y
_O}m0c
3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£